vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and ECB Bancorp, Inc. (ECBK). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $9.5M, roughly 2.0× ECB Bancorp, Inc.). ECB Bancorp, Inc. runs the higher net margin — 27.3% vs -0.8%, a 28.1% gap on every dollar of revenue. On growth, ECB Bancorp, Inc. posted the faster year-over-year revenue change (33.8% vs -25.7%). ECB Bancorp, Inc. produced more free cash flow last quarter ($9.0M vs $-15.8M). Over the past eight quarters, ECB Bancorp, Inc.'s revenue compounded faster (23.8% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.
CTMX vs ECBK — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $9.5M |
| Net Profit | $-154.0K | $2.6M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 36.7% |
| Net Margin | -0.8% | 27.3% |
| Revenue YoY | -25.7% | 33.8% |
| Net Profit YoY | 97.6% | 79.5% |
| EPS (diluted) | — | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $9.5M | ||
| Q3 25 | — | $8.8M | ||
| Q2 25 | $18.7M | $8.0M | ||
| Q1 25 | $50.9M | $6.9M | ||
| Q4 24 | $38.1M | $7.1M | ||
| Q3 24 | $33.4M | $6.6M | ||
| Q2 24 | $25.1M | $6.3M | ||
| Q1 24 | $41.5M | $6.2M |
| Q4 25 | — | $2.6M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | $-154.0K | $1.4M | ||
| Q1 25 | $23.5M | $1.3M | ||
| Q4 24 | $18.9M | $1.4M | ||
| Q3 24 | $5.7M | $1.1M | ||
| Q2 24 | $-6.5M | $791.0K | ||
| Q1 24 | $13.8M | $621.0K |
| Q4 25 | — | 36.7% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | -6.9% | 23.9% | ||
| Q1 25 | 44.4% | 24.9% | ||
| Q4 24 | 46.4% | 27.3% | ||
| Q3 24 | 12.3% | 23.3% | ||
| Q2 24 | -33.7% | 16.9% | ||
| Q1 24 | 28.1% | 13.4% |
| Q4 25 | — | 27.3% | ||
| Q3 25 | — | 27.7% | ||
| Q2 25 | -0.8% | 18.0% | ||
| Q1 25 | 46.2% | 18.7% | ||
| Q4 24 | 49.6% | 20.3% | ||
| Q3 24 | 17.2% | 17.2% | ||
| Q2 24 | -26.0% | 12.6% | ||
| Q1 24 | 33.3% | 10.0% |
| Q4 25 | — | $0.32 | ||
| Q3 25 | — | $0.29 | ||
| Q2 25 | — | $0.17 | ||
| Q1 25 | — | $0.16 | ||
| Q4 24 | — | $0.18 | ||
| Q3 24 | — | $0.14 | ||
| Q2 24 | — | $0.09 | ||
| Q1 24 | — | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $82.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $171.9M |
| Total Assets | $175.1M | $1.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $82.8M | ||
| Q3 25 | — | $201.9M | ||
| Q2 25 | $49.0M | $191.0M | ||
| Q1 25 | $47.6M | $143.7M | ||
| Q4 24 | $38.1M | $309.4M | ||
| Q3 24 | $40.6M | $114.8M | ||
| Q2 24 | $43.2M | $108.7M | ||
| Q1 24 | $36.2M | $109.8M |
| Q4 25 | — | $171.9M | ||
| Q3 25 | — | $169.3M | ||
| Q2 25 | $119.9M | $168.3M | ||
| Q1 25 | $25.0M | $168.6M | ||
| Q4 24 | $-456.0K | $168.3M | ||
| Q3 24 | $-23.5M | $166.0M | ||
| Q2 24 | $-31.2M | $166.5M | ||
| Q1 24 | $-31.7M | $165.8M |
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | $175.1M | $1.5B | ||
| Q1 25 | $98.5M | $1.5B | ||
| Q4 24 | $120.5M | $1.4B | ||
| Q3 24 | $139.0M | $1.4B | ||
| Q2 24 | $159.2M | $1.3B | ||
| Q1 24 | $184.7M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $9.2M |
| Free Cash FlowOCF − Capex | $-15.8M | $9.0M |
| FCF MarginFCF / Revenue | -84.6% | 94.7% |
| Capex IntensityCapex / Revenue | 0.1% | 2.2% |
| Cash ConversionOCF / Net Profit | — | 3.55× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $14.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $9.2M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | $-15.8M | $1.9M | ||
| Q1 25 | $-21.0M | $-631.0K | ||
| Q4 24 | $-19.9M | $6.2M | ||
| Q3 24 | $-20.7M | $861.0K | ||
| Q2 24 | $-19.5M | $1.4M | ||
| Q1 24 | $-26.0M | $-429.0K |
| Q4 25 | — | $9.0M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | $-15.8M | $1.8M | ||
| Q1 25 | $-21.2M | $-649.0K | ||
| Q4 24 | $-20.0M | $6.2M | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | $1.3M | ||
| Q1 24 | $-26.2M | $-449.0K |
| Q4 25 | — | 94.7% | ||
| Q3 25 | — | 44.9% | ||
| Q2 25 | -84.6% | 23.0% | ||
| Q1 25 | -41.6% | -9.4% | ||
| Q4 24 | -52.5% | 86.8% | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | 21.4% | ||
| Q1 24 | -63.1% | -7.2% |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | 0.1% | 0.6% | ||
| Q1 25 | 0.2% | 0.3% | ||
| Q4 24 | 0.2% | 0.8% | ||
| Q3 24 | 0.1% | 0.0% | ||
| Q2 24 | 0.4% | 0.6% | ||
| Q1 24 | 0.3% | 0.3% |
| Q4 25 | — | 3.55× | ||
| Q3 25 | — | 1.65× | ||
| Q2 25 | — | 1.32× | ||
| Q1 25 | -0.89× | -0.49× | ||
| Q4 24 | -1.05× | 4.31× | ||
| Q3 24 | -3.61× | 0.76× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | -1.89× | -0.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
ECBK
Segment breakdown not available.
